EBIT at other companies
Other financials
Where this comes from
Calculated from Capricor Therapeutics’s reported figures.
Plus components not separately reported this period.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's EBIT?
- Capricor Therapeutics (CAPR) reported EBIT of -$36.77M in Q1 2026.
- How has Capricor Therapeutics's EBIT changed year-over-year?
- Capricor Therapeutics's EBIT decreased by 47.2% year-over-year, from -$24.98M to -$36.77M.
- What is the long-term trend for Capricor Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Capricor Therapeutics's EBIT has grown at a 50.8% compound annual growth rate (CAGR), from -$20.94M to -$108.14M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.